New Needle for Two-Needle Hemodialysis
BME-1
2 other identifiers
interventional
70
1 country
1
Brief Summary
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the standard venous needle because it decreases the velocity and turbulence of the blood when compared with the standard venous needle, it is more efficient in the removal of toxins from the blood, and it is safe and effective. More importantly, our preliminary studies suggested that the new needle causes less damage to the dialysis vascular access and to circulating blood cells and less inflammation and oxidative stress. These will decrease medical complications, the high cost of care and death in dialysis patients. The current study will corroborate the finding of previous studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Aug 2011
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 9, 2011
CompletedFirst Posted
Study publicly available on registry
August 15, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedAugust 15, 2011
August 1, 2011
1.1 years
August 9, 2011
August 12, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Net change in intracellular oxidative stress and intracellular proinflammatory cytokines levels
The net change in the levels of intracellular IL-6, IL-6 soluble receptor, IL-6 gp130, superoxide, H2O2 and IL-1 during dialysis (difference between pre and post dialysis) using the new venous needle will be compared with the change using the current venous needle.
4 hours of hemodialysis
Secondary Outcomes (1)
Net change in oxidative stress and proinflammatory cytokines in plasma
4 hours hemodialysis
Study Arms (2)
New venous needle, the "BME needle"
EXPERIMENTALHemodialysis using the new venous needle, the "BME needle".
Standard venous needle, the "standard needle"
ACTIVE COMPARATOROne hemodialysis using the standard venous needle, the "standard needle" (device).
Interventions
Hemodialysis using the standard venous dialysis needle
Hemodialysis using a new venous dialysis needle or the "BME needle"
Eligibility Criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
DaVita K Street Dialysis Center
Washington D.C., District of Columbia, 20037, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alfredo R Zarate, MD
Biomedical Enterprises Inc
- PRINCIPAL INVESTIGATOR
Pedro A Jose, MD, PhD
Children National Medical Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 9, 2011
First Posted
August 15, 2011
Study Start
August 1, 2011
Primary Completion
September 1, 2012
Study Completion
September 1, 2012
Last Updated
August 15, 2011
Record last verified: 2011-08